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Introduction
Persistent infection with an oncogenic human papilloma-
virus (HPV) type is a prerequisite for developing cervical 
cancer (CC) [1]. The latter is the fourth most common 
cancer in females worldwide [2]. To date, at least 13 HPV 
types have been defined as oncogenic. Among them, HPV- 
16 and HPV- 18 are estimated to contribute to 71% of 
invasive CC cases [3].
The AS04- HPV- 16/18 vaccine (Cervarix, GSK, 
Belgium) is licensed for administration from the age of 
9 years in most countries, with an upper age limit 
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Abstract
Women remain at risk of human papillomavirus (HPV) infection for most of 
their lives. The duration of protection against HPV- 16/18 from prophylactic 
vaccination remains unknown. We investigated the 10- year immune response 
and long- term safety profile of the HPV- 16/18 AS04- adjuvanted vaccine (AS04- 
HPV- 16/18 vaccine) in females aged between 15 and 55 years at first vaccination. 
Females who received primary vaccination with three doses of AS04- HPV- 16/18 
vaccine in the primary phase- III study (NCT00196937) were invited to attend 
annual evaluations for long- term immunogenicity and safety. Anti- HPV- 16/18 
antibodies in serum and cervico- vaginal secretions (CVS) were measured using 
enzyme- linked immunosorbent assay (ELISA). Serious adverse events (SAEs) were 
recorded throughout the follow- up period. Seropositivity rates for anti- HPV- 16 
remained high (≥96.3%) in all age groups 10 years after first vaccination. It was 
found that 99.2% of 15–25- year olds remained seropositive for anti- HPV- 18 
compared to 93.7% and 83.8% of 26–45- year olds and 45–55- year olds, respec-
tively. Geometric mean titers (GMT) remained above natural infection levels in 
all age groups. Anti- HPV- 16 and anti- HPV- 18 titers were at least 5.3- fold and 
3.1- fold higher than titers observed after natural infection, respectively, and were 
predicted to persist above natural infection levels for ≥30 years in all age groups. 
At Year 10, anti- HPV- 16/18 antibody titers in subjects aged 15–25 years remained 
above plateau levels observed in previous studies. Correlation coefficients for 
antibody titers in serum and CVS were 0.64 (anti- HPV- 16) and 0.38 (anti- 
HPV- 18). This study concluded that vaccinated females aged 15–55 years elicited 
sustained immunogenicity with an acceptable safety profile up to 10 years after 
primary vaccination, suggesting long- term protection against HPV.
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varying from 25 years to no limit [4, 5]. Current vac-
cination programs worldwide target young adolescents 
before they become sexually active and exposed to HPV. 
Nevertheless, due to the continuous risk of acquiring 
new infections throughout a woman’s active sexual life, 
CC screening and vaccination against HPV in older 
women could also be effective against development of 
CC [6–8]. The primary phase- III study (NCT00196937) 
demonstrated that the AS04- HPV- 16/18 vaccine was 
immunogenic and well tolerated in females aged 
15–55 years [9]. The follow- up study showed that anti- 
HPV- 16/18 antibodies in serum and cervico- vaginal 
secretions (CVS) persisted for 6 years after vaccination 
in this population with an acceptable safety profile [10]. 
In a study involving women above 25 years of age, the 
vaccine also demonstrated protection against HPV- 16 
and HPV- 18 persistent infections, cytological abnormali-
ties, and CIN1+  (NCT00294047) [11].
As the exact duration of protection against HPV- 16 
and - 18 following the HPV- 16/18 AS04- adjuvanted vaccine 
administration was unknown at licensure, long- term follow-
 up studies were conducted. This study evaluated the 10- 
year immune persistence and long- term safety of the 
vaccine in women aged 15–55 years at the time of the 
first vaccination.
Material and Methods
Study design and subjects
The primary, open, phase- III, age- stratified study, which 
was conducted at three centers in Germany and Poland, 
vaccinated females aged 15–55 years with three doses of 
the AS04- HPV- 16/18 vaccine according to a 0- , 1- , and 
6- month schedule (NCT00196937). All subjects who 
received three doses of the vaccine in the primary study 
were invited to return for annual immunogenicity and 
safety evaluations from Year 5 onward. This study was 
designed to provide 10- year follow- up of immunogenicity 
and safety (NCT00947115) in these subjects. Females who 
missed an annual visit remained eligible for inclusion at 
a later time point.
Subjects were not enrolled in the study if they had 
received previous vaccination against HPV other than 
the AS04- HPV- 16/18 vaccine, or chronic administration 
of immunosuppressants, immunoglobulins, or blood 
products less than 3 months prior to blood 
sampling.
The study was conducted in accordance with the 
Declaration of Helsinki, principles of Good Clinical Practice 
(GCP), and all applicable regulatory requirements. Written 
informed consent was obtained from each subject before 
conducting any study- specific procedures.
Immunogenicity assessment
At each annual visit (Years 5, 6, 7, 8, 9, and 10), a 10- 
mL sample of whole blood was taken from each subject 
and CVS samples were also collected in consenting subjects 
who volunteered for this additional procedure as already 
described in the primary publication [9]. The presence of 
anti- HPV- 16/18 antibodies were evaluated using an enzyme- 
linked immunosorbent assay (ELISA). Overtime stability 
of the validated HPV- 16/18 ELISA assays on serum and 
CVS was monitored by in process controls tested on each 
ELISA plate and a quality control panel testing every 
6 months. This monitoring enables the direct comparison 
of antibody levels across studies. Until Year 7, seropositivity 
was defined as antibody titers ≥8 EU/mL and ≥7 EU/mL 
for anti- HPV- 16 and anti- HPV- 18 antibodies, respectively. 
While monitoring the quality of the assay, a high variability 
was observed in the low range of assay results from unvac-
cinated trial participants. From Year 8 onward, the preci-
sion of the assay was therefore increased by changing the 
seropositivity cut- offs to antibody titers ≥19 EU/mL and 
≥18 EU/mL for anti- HPV- 16 and anti- HPV- 18, respectively. 
Subjects with antibody titers below the assay cut- off were 
assigned an arbitrary GMT value of half the cut- off for 
the purpose of GMT calculations.
Safety assessment
Long- term safety of the AS04- HPV- 16/18 vaccine up to 
10 years after first vaccination was evaluated. The analysis 
of safety was based on the TVC comprising all vaccinated 
subjects who received three doses of the AS04- HPV- 16/18 
vaccine in the primary study and participated in the Year-10 
extension study.
A serious adverse event (SAE) was defined as any unto-
ward medical event that resulted in death, was life- 
threatening, required hospitalization or prolongation of 
existing hospitalization, or resulted in disability/incapacity. 
Medical or scientific judgment was exercised in deciding 
whether reporting was appropriate in other situations such 
as important medical events that may not have been 
immediately life- threatening or resulted in death or hos-
pitalization but may have jeopardized the subject or may 
have required medical or surgical intervention. In such 
cases, these events were also considered serious. Any 
vaccine- related, study participation- related, or GSK con-
comitant medication- related SAEs or fatal SAEs were 
recorded throughout the study period.
Statistical analyses
The primary endpoint was the evaluation of long- term 
immunogenicity of the HPV- 16/18 vaccine in serum from 
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all vaccinated subjects by ELISA at each time point (Years 
5, 6, 7, 8, 9, and 10) following the first vaccine dose. 
The according- to- protocol (ATP) cohort for analysis of 
immunogenicity included all evaluable subjects, that is, 
subjects included in the ATP immunogenicity analysis 
during the primary study (NCT00196937), who met all 
eligibility criteria, complied with the study procedures 
defined in the protocol, had no elimination criteria during 
the study and in whom serology results were available.
Seropositivity rates and geometric mean titers (GMTs) 
were calculated with exact 95% confidence intervals (CIs) 
for anti- HPV- 16/18 antibodies. Secondary analyses com-
pared the immune response of subjects to the AS04- 
HPV- 16/18 vaccine in this study (NCT00947115) with 
the immunogenicity plateau levels measured in the efficacy 
study (NCT00689741) and associated long- term follow- up 
studies (NCT00120848, NCT00518336) [12–14], and the 
immune response measured after natural infection in 
subjects from the PATRICIA study (NCT00122681) [15], 
in which efficacy was demonstrated in women aged 
15–25 years [16]. GMT values from CVS samples up to 
10 years after first vaccination were evaluated. CVS sam-
ples with Hemastix values ≥200 erythrocytes per μL were 
excluded from antibody testing as they were considered 
to be contaminated with blood. The analysis of immu-
nogenicity of CVS samples was based on the total vac-
cinated cohort (TVC) that was comprised of subjects 
who volunteered for CVS sampling and for whom CVS 
results were available. Anti- HPV- 16/18 antibody titers 
were determined in both serum and CVS samples. Since 
antibody levels fluctuate during menstrual cycles, indi-
vidual anti- HPV- 16 and anti- HPV- 18 titers were divided 
by the total IgG concentration, to evaluate the correlation 
between vaccine- induced IgG titers in serum and CVS 
[9, 17, 18].
Mathematical modeling
Post hoc mathematical modeling was conducted to evalu-
ate long- term immunogenicity against HPV- 16 and HPV- 
18 for at least 30 years after vaccination. Two different 
mixed effects models were used, piecewise and modified 
power- law (Fraser) [19]. The piecewise model used a linear 
function in which the data were fitted on four non- 
overlapping time intervals (with breakpoints at months 
7, 12, 21, and 48) that corresponded to the observed 
decay of humoral antibodies. The previous modeling with 
6- year data included three breakpoints (months 7, 12, 
and 21) in the piecewise model that predicted population 
antibody responses above the natural infection antibody 
level for up to 20 years [20]. As our results provided 
data for up to 10 years, one more piece or breakpoint 
was defined for the piecewise model. The selection of the 
additional breakpoint, that is, month 48, was based on 
the Akaike Information Criteria [21]. The modified power- 
law method that estimated antibody decay over time after 
vaccination was based on the dynamic populations of 
B- cells (activated and memory B- cells) that account for 
long- term persistence and antibody plateau. The piecewise 
and modified power- law models were fitted using MIXED 
and NLMIXED statistical analyses system procedures, 
respectively.
Results
Subject disposition and demographics
Of 666 subjects from Germany and Poland who received 
three doses of the AS04- HPV- 16/18 vaccine in the primary 
study, 524 participated in the trial and were included in 
the TVC cohort for safety analysis. Among them, 470 
completed the Year 10 assessment, that is, Year 10 TVC, 
and 451 were included in the Year 10 ATP cohort for 
immunogenicity (Fig. S1). Subjects were stratified accord-
ing to age and the TVC cohort included 142 subjects in 
the 15–25- year age group, 172 in the 26–45- year age 
group, and 156 in the 46–55- year age group. Mean age 
at Year 10 was 30.6 years (standard deviation, SD: 2.8), 
46.1 years (SD: 6.0) and 59.6 years (SD: 2.8) in the three 
age groups, respectively. The population was predomi-
nantly Caucasian.
Immunogenicity
Seropositivity rates for anti- HPV- 16 remained high 
(≥96.3%) in all age groups 10 years after first vaccination 
(Table 1). For anti- HPV- 18, 99.2% of subjects in the 
15–25- year age group remained seropositive compared 
with 93.7 and 83.8% in the 26–45 and 46–55- year age 
groups, respectively.
Serum anti- HPV- 16 antibody levels at Year 10 appeared 
to be lower [non- overlapping CIs] in the older group 
(157.4 EU/mL, 95% CI: 128.4; 193.1) compared with the 
26–45 and 15–25- year age groups, that is, 334.4 EU/mL 
(95% CI: 270.5; 413.5) and 965.4 EU/mL (802.2; 1161.8), 
respectively [non- overlapping CIs]. A similar pattern of 
change was seen with serum HPV- 18 antibody levels as 
shown in Table 2, that is, 69.7 EU/mL (95% CI: 56.0; 
86.8) in the 46–55- year age group, 115.4 EU/mL (95% CI: 
93.9; 142.0) in the 26–45- year age group, and 321.1 EU/
mL (95% CI: 265.0; 389.1) in the 15–25 year- group (non- 
overlapping CIs). The antibody kinetics of both anti- HPV- 16 
and anti- HPV- 18 at Year 10 are shown in Figure 1. Following 
a peak in antibody levels 1 month after third vaccination, 
there was a gradual decline for both antigens, which pla-
teaued after 2 years. GMTs in all age groups remained 
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above natural infection levels. Anti- HPV- 16 and anti- 
HPV- 18 antibody titers were at least 5.3- fold (95% CI: 
4.2–6.6) and 3.1- fold (95% CI: 2.5–3.7) higher than the 
titers observed after natural infection, respectively. (Table 3)
In subjects vaccinated at the age of 15–25, anti- HPV- 16 
antibody titers at Year 10 remained above the plateau 
levels observed in previous efficacy studies (NCT00689741, 
NCT00120848, NCT00518336).










LL UL LL UL LL UL
Anti- HPV- 16 100 97.0 100 99.2 95.5 100 96.3 90.7 99.0
Anti- HPV- 18 99.2 95.7 100 93.7 88.3 97.1 83.8 76.4 89.7
95% CI: 95% confidence interval.
LL, Lower limit; UL, Upper limit; HPV, Human Papillomavirus.
Table 2. Anti- HPV- 16 and anti- HPV- 18 serum and cervico- vaginal secretions antibody levels at Year 10 (serum: According to protocol cohort for im-








n (N)LL UL LL UL
HPV–16
 [15–25] 965.4 802.2 1161.8 123 (123) 43.4 28.1 67.1 29 (40)
 [26–45] 334.4 270.5 413.5 120 (121) 34.3 24.1 48.7 22 (37)
 [46–55] 157.4 128.4 193.1 103 (107) 56.0 31.5 99.7 13 (24)
HPV–18
 [15–25] 321.1 265.0 389.1 126 (127) 29.4 17.6 49.4 16 (40)
 [26–45] 115.4 93.9 142.0 133 (142) 22.7 13.8 37.3 16 (37)
 [46- 55] 69.7 56.0 86.8 109 (130) 45.1 22.9 88.6 8 (24)
1CVS: cervico- vaginal secretion sample with hemastix < 200 erythrocytes per μL. GMT: Geometric mean titer (EU/mL); 95% CI: 95% confidence interval; LL: 
Lower limit; UL: Upper limit; HPV: Human Papillomavirus; N: number of subjects with available results; n: number of subject with titre equal to or above the 
lower limit of quantitation in CVS at 0.58 EU/mL for HPV- 16 and 0.35 EU/mL for HPV- 18 and in serum 19 EU/mL for HPV- 16 and 18 EU/mL for HPV- 18
Figure 1. Long- term kinetics of anti- HPV- 16 (left) and anti- HPV- 18 (right) antibodies (According to protocol [ATP] cohort for immunogenicity). Plateau 
levels (dashed lines) are 418.3 EU/mL and 242.6 EU/mL for HPV- 16 and HPV- 18, respectively (month 107–113 in reference study) [13, 14, 16]. Natural 
infection levels (solid lines) are 29.8 EU/mL and 22.7 EU/mL for HPV- 16 and HPV- 18, respectively [15]. CI, confidence interval; GMT, geometric mean 
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At Year 10, anti- HPV- 16 antibody titers in initially 
seronegative subjects from the Y10 ATP cohort for immu-
nogenicity were 2.31- fold (95% CI: 1.76, 3.03) higher in 
the 15–25- year age group, 0.80- fold lower (95% CI: 0.59, 
1.07) in the 26–45- year age group and 0.38- fold lower 
(95% CI: 0.28, 0.50) in the 46–55- year age group com-
pared to those measured at the end of the 113- month 
(≈ 9.4- year) follow- up in subjects vaccinated at the age 
of 15–25 years in the efficacy and long- term follow- up 
studies. Anti- HPV- 18 antibody titers were found to be 
1.32- fold higher (95% CI: 1.00, 1.75) in the 15–25- year 
age group, 0.48- fold lower (95% CI: 0.35, 0.64) in the 
26–45- year age group, and 0.29- fold lower (95% CI: 0.21, 
0.39) in the 46–55- year age group as compared to the 
same reference. In older age groups, that is, 26–45 and 
46–55, antibody titers were similar to or below the plateau 
levels for HPV- 16 and HPV- 18 antigens (Fig. 1).
At Year 10, 107 women (15–25 years: 41; 26–45 years: 
40; 46–55 years: 26) provided CVS samples with <200 
erythrocytes/μL, which were suitable for HPV antibody 
testing. At this time point, anti- HPV- 16 antibodies were 
detected in 70.7 (n = 29), 57.5 (n = 23), and 53.8% 
(n = 14) of CVS samples of women from the 15–25, 
26–45, and 46–55- year age groups, respectively. Anti- 
HPV- 18 antibodies were detected in 39.0, 45.0, and 34.6% 
of the CVS samples, respectively.
Overall, correlation coefficients for anti- HPV- 16 and 
anti- HPV- 18 antibody titers between serum and CVS 
samples were 0.64 and 0.38, respectively.
Table 3. Comparison of the elicited immune responses against HPV- 16 
and HPV- 18 with the observed geometric mean titers after natural in-










 [15–25] 965.4 29.8 32.4 26.3 39.9
 [26–45] 334.4 29.8 11.2 9.1 13.8
 [46–55] 157.4 29.8 5.3 4.2 6.6
HPV–18
 [15–25] 321.1 22.7 14.1 11.8 17.0
 [26–45] 115.4 22.7 5.1 4.3 6.1
 [46–55] 69.7 22.7 3.1 2.5 3.7
1GMTs: Geometric mean titers (EU/mL) for anti- HPV- 16 antibodies and 
anti- HPV- 18 antibodies at Year 10 time point for subjects seronegative 
before vaccination.
2Geometric mean titer value associated with natural infection[9] . 95% 
CI: 95% confidence interval; LL: Lower limit; UL: Upper limit; HPV: 
Human Papillomavirus.
Figure 2. Anti- HPV- 16/18 antibody titers predicted by the piecewise (A, B) or modified power- law (C, D) models up to 30 years after the first vaccine 
dose in subjects who received all three doses of HPV vaccine, by age group. The horizontal line indicates the mean antibody titer associated with 

























































Time since first dose (year)



















Time since first dose (year)
Time since first dose (year)
Time since first dose (year)
26–45 Y 46–55 Y 15–25 Y 26–45 Y 46–55 Y 15–25 Y
A B
C D
2728 © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
T. F. Schwarz et al.Ten- year Follow- up of HPV Vaccination
Mathematical modeling
The results of extrapolating anti- HPV- 16 and anti- HPV- 18 
antibody titers to at least 30 years after the first vaccine 
dose are shown in Figure 2. The modified power- law 
model predicted that mean antibody titers would remain 
above the levels associated with natural infection in a 
previous study in all three age groups [22]. The piecewise 
model, which takes into account a decrease in antibody 
levels over time, predicted that mean antibody levels would 
remain above natural infection levels in the two younger 
age groups, but not in the older, at Year 30. More spe-
cifically, this model projected that antibody levels would 
remain above natural infection levels for 38.8, 17.8, and 
12.4 years with anti- HPV- 16 and 28.8, 11.3, and 4.4 years 
with anti- HPV- 18 for 95% of women aged 15–25, 26–45, 
and 46–55 years, respectively.
The modified power- law model predicted that anti- 
HPV- 16 levels would remain above the natural infection 
level lifelong in females aged 15–45 years and for up to 
31.4 years in those aged 46–55 years. Similarly, this model 
projected that anti- HPV- 18 levels would remain above 
the natural infection level lifelong in females aged 15–25, 
while the predicted time that 95% of women would still 
have anti- HPV- 18 levels above natural infection levels was 
25.9 and 3.58 years in the 26–45 and 46–55- year age 
groups, respectively (Table 4).
Safety
Two deaths were recorded over the 10- year follow- up period 
due to chronic lymphocytic leukemia and malignant lung 
neoplasm. None of these fatal SAEs were considered to be 
related to vaccination by the investigator. One case of cervical 
dysplasia of moderate severity, which was detected 8.4 years 
after the first vaccine dose in a 36- year- old female, was clas-
sified as vaccine- related SAE by the investigator. Polymerase 
chain reaction (PCR) on biopsy indicated the presence of 
high- risk HPV although the type causing the lesion could 
not be identified (PCR mix). The subject was HPV- 16 sero-
positive and of unknown DNA status at baseline. This event 
had resolved by the end of the study. (Table S1).
Discussion
Findings
This is the first study to examine the 10- year immune 
persistence and safety of the AS04- HPV- 16/18 vaccine 
administered to women up to 55 years of age.
Ten years after receiving the first vaccination, most subjects 
were still seropositive for HPV- 16/18 in all age groups. 
Antibody kinetics had similar profiles across all age groups, 
displaying a decline in GMT values with increasing ages at 
first vaccination. As previously observed in the same study, 
a more or less potent correlation was observed between the 
anti- HPV- 16/18 antibody levels in the serum and CVS sam-
ples, further supporting the previous observation of long- 
lasting transudation of serum antibodies across the cervical 
epithelium, although this association was not as strong as 
that seen at the Year 6 time point and was quite weak for 
HPV- 18, presumably as a result of a smaller number of 
evaluable samples at the Year 10 time point [10, 18, 23].
The long- term safety profile of the vaccine was clini-
cally acceptable. The occurrence of cervical dysplasia was 
of unclear clinical significance as the subject had already 
been infected by HPV- 16 before vaccination and no base-
line DNA testing was performed at study entry. It is not 
known if the lesion was the result of a reactivation or a 
new infection by a high- risk HPV type.
Strengths and limitations
This study confirmed, for the first time, the long- term 
persistence of anti- HPV- 16/18 antibodies in women 
Table 4. Predicted anti- HPV- 16 and anti- HPV- 18 antibody responses by piecewise and modified power- law models for the three age groups.
Age group 
(years)
HPV- 16 HPV- 18
Piecewise model Modified power- law model Piecewise model Modified power- law model
Predicted GMT 







GMT at Year 






at Year 30 












[15–25] 230.759 38.83 863.619 >30 95.849 28.83 282.830 >30
[26–45] 58.875 17.83 340.753 >30 31.232 11.25 120.952 25.92
[46–55] 27.424 12.42 203.413 31.41 <18 (17.47) 4.42 68.239 3.58
GMT, geometric mean titer; HPV, Human Papillomavirus.
1Predicted time ensuring 95% of women will still have predicted titers above natural infection level (29.8 EU/mL for HPV- 16, 22.7 EU/mL for 
HPV- 18).
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vaccinated up to the age of 55. The study was further 
strengthened by the collection of serum and CVS samples 
that allowed for correlation of antibody titers, although 
few CVS samples were collected and evaluable at study 
end. It was limited by the lack of cervical screening at 
enrolment and the absence of clinical or virological 
endpoints.
Interpretation
Ten years after first vaccination, the AS04- HPV- 16/18 vac-
cine showed sustained immunogenicity in all age groups. 
Antibody titers at Year 10 were still at least three times 
higher than those observed after natural infection across all 
age groups, and in the older age categories (≥25 years), titers 
were similar to or just below the plateau levels associated 
with long- term efficacy [14, 22]. These findings were in line 
with the results of the primary study and consistent with 
our expectations, since GMTs are known to decline with 
increasing age at vaccination [9]. These results, along with 
the sustained efficacy seen in another study for up to 7 years 
post vaccination in women aged ≥25 years, suggest that the 
vaccine may confer protection for up to 10 years and pos-
sibly longer, even in older subjects [11].
Mathematical modeling predicted detectable anti- 
HPV- 16 and anti- HPV- 18 antibody responses for at least 
30 years after the first vaccination. Since women are 
potentially at risk of exposure to HPV for a long period 
of time throughout their lives, these findings suggest that 
the duration of protection against CC conferred by HPV 
vaccination may be close to lifelong.
Conclusion
This study confirmed the sustained immunogenicity of 
the AS04- HPV- 16/18 vaccine in women aged 15–55 years, 
with an acceptable safety profile for at least 10 years after 
primary vaccination. Mathematical modeling predicted that 
anti- HPV- 16/18 antibody titers, 30 years post vaccination 
would still be above natural infection levels in all age 
groups using a modified power- law model, and in the 
15–25 years and 26–45- year age groups using a piecewise 
model. Considering the time required to develop cervical 
cancer, this suggests that protection may be close to life-
long. Women in age groups not targeted by pediatric or 
adolescent immunization and catch- up programs may still 
individually benefit from HPV vaccination.
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